CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
i
Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults (EXIT-CJS)
-
9 2021
-
-
Source: J Subst Abuse Treat. 128:108389
[PDF-840.81 KB]
Details:
-
Alternative Title:J Subst Abuse Treat
-
Personal Author:
-
Description:The EXIT-CJS (N = 1005) multisite open-label randomized controlled trial will compare retention and effectiveness of extended-release buprenorphine (XR-B) vs. extended-release naltrexone (XR-NTX) to treat opioid use disorder (OUD) among criminal justice system (CJS)-involved adults in six U.S. locales (New Jersey, New York City, Delaware, Oregon, Connecticut, and New Hampshire). With a pragmatic, noninferiority design, this study hypothesizes that XR-B (n = 335) will be noninferior to XR-NTX (n = 335) in retention-in-study-medication treatment (the primary outcome), self-reported opioid use, opioid-positive urine samples, opioid overdose events, and CJS recidivism. In addition, persons with OUD not eligible or interested in the RCT will be recruited into an enhanced treatment as usual arm (n = 335) to examine usual care outcomes in a quasi-experimental observational cohort.
-
Keywords:
-
Source:
-
Pubmed ID:33865691
-
Pubmed Central ID:PMC8384640
-
Document Type:
-
Funding:
-
Volume:128
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type:
